Maureen Waterfall

1. 1. lack of licensed antidote for Edoxaban

   “heard evidence from MM Clinical Director of Neurosciences at Salford Royal Hospital. He told me that Edoxaban was one of the new anticoagulant drugs, but of those with which he is familiar, it is differentiated by the fact that there is no currently licensed antidote. He is aware of clinical trials being undertaken of such an antidote.”

2. 2. continued bleeding to the brain in head injury patients on Edoxaban

   “head injury patients who are prescribed Exodaban are at greater risk of continued bleeding to the brain than other patients as the absence of a specific antidote makes the reversal of the anticoagulant medication less certain. As with other newer anticoagulant drugs, there is little ability to monitor the effectiveness of the antidote. It was unclear if that understanding had been shared widely amongst non-tertiary centres to assist them in managing such patients”

3. 3. inadequate storage location of anticoagulant antidote drugs

   “there is no national standard guidance about the storage of supplies of anticoagulant antidote drugs. As a result, as in this case at Tameside General Hospital Accident and Emergency Department they were not kept at the resuscitation unit, but rather they were kept in the haematology department”

No published response was found on judiciary.uk.